Mutations in the gene KRAS are the most frequent drivers of tumour development across the spectrum of human cancers 1 . Despite this prevalence, mutant KRAS protein has remained an intractable thera peutic target. Writing in Nature, Canon et al. 2 describe a small molecule that binds one form of mutant KRAS with high specificity and sensi tivity, inhibiting the protein. The authors use animal models to analyse how the inhibitor works, and show that it can shrink tumours in patients. This is among the first evidence of a clinical response to a specific KRAS inhibitor.
KRAS is an enzyme that controls a signalling pathway crucial for cell growth, differentia tion and survival. The inactive protein is bound by a guanosine diphosphate (GDP) molecule -replacement of GDP by guanosine triphosphate (GTP) facilitates conformational changes in KRAS that allow the enzyme to bind and activate downstream effector mol ecules ( Fig. 1a ). Nearly all cancerpromoting KRAS mutations prevent GTP breakdown, leaving KRAS in a permanently active state 3 (Fig. 1b ). One such mutation involves substi tution of a glycine aminoacid residue for a cysteine residue. The resulting mutant pro tein, KRAS G12C , is found infrequently in various cancers. It is most prevalent in lung cancer, and is responsible for approximately 12% of nonsmall cell lung cancers 4, 5 .
In the past few years, several irreversible smallmolecule inhibitors have been devel oped [6] [7] [8] that bind covalently to a pocket in GDPbound KRAS G12C to inhibit GTP binding. These inhibitors successfully prevent activation of the protein in animal models, but none has had any effect on tumours in patients. Canon et al. characterized another smallmolecule inhibitor, AMG 510, that forms a covalent bond with GDPbound KRAS G12C (Fig. 1c) . AMG 510 has similar structural properties to one of the previous inhibitors, ARS1620, but has one key difference -it binds a structure called a cryptic surface groove that forms in KRAS G12C , and so recognizes the mutant protein with high specificity.
The authors showed that AMG 510 inhibits the exchange of GDP for GTP more potently than does ARS1620. Moreover, AMG 510 strongly inhibits phosphorylation of the protein ERK (a known effector of KRAS activ ity) in cells harbouring KRAS G12C , and impairs cell proliferation.
Next, Canon and colleagues turned to mice carrying KRAS G12C tumour cells taken from patients. Treatment with AMG 510 at a con centration of 100 milligrams per kilogram of body weight resulted in tumour regression, but the cancer subsequently returned. At 200 mg kg −1 , however, AMG 510 triggered permanent tumour regression in eight out of ten mice. Of note, the robust potency with which AMG 510 triggers cell death raises the possibility that it becomes covalently attached to other cysteinecontaining proteins, in addi tion to KRAS G12C -something that should be investigated in future, if the molecule is to be regularly used in patients.
Interestingly, mice showed a durable response to the 200 mg kg −1 AMG 510 treat ment only if they had a functioning immune system (known as immune competence). In mice lacking the immune cells called T cells, tumours returned. This led the authors to Medical research 'Undruggable' cancer protein targeted
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A molecule has now been characterized that acts to inhibit a cancercausing form of KRAS protein and stimulate the immune system. The inhibitor is one of the first of its kind to show anticancer activity in the clinic. ask whether it would be possible to combine AMG 510 with an immunotherapy called antiPD1 therapy, which harnesses the immune system to combat cancer. Indeed, treatment with AMG 510 at 100 mg kg −1 combined with antiPD1 therapy resulted in complete tumour regression in nine out of ten immunecompetent mice. Canon and colleagues found that AMG 510 treatment boosted the expression of inflam matory molecules called chemokines in the animals' tumours. This was associated with an increase in infiltration of the tumours by T cells and dendritic cells, both of which are involved in the immune system's response to cancer. Furthermore, when the authors rein troduced KRAS G12C cancer cells to mice that had been cured by the combination treatment, no tumours grew. This suggests that the com bination treatment established a longterm Tcell response to KRAS G12C tumour cells. The researchers could also improve the cure rate and efficacy of AMG 510 treatment by com bining it with a standard chemotherapy drug or with a drug that inhibits the protein MEK, which acts downstream of KRAS.
These data served as the cornerstone for AMG 510 trials in the clinic. Canon et al. describe clinical results for four people who have nonsmall cell lung cancer. All four harbour the KRAS G12C mutation and were treated with AMG 510. This is a very small number of patients, but the results are prom ising. In two of the four patients, the cancer stopped growing. The other two showed a partial response -their tumours shrank by 34% and 67% after six weeks. At the point at which the authors stopped collecting data, these patients had been receiving AMG 510 for 39 and 26 weeks, respectively, and were still taking the drug.
Canon and colleagues' findings are supported by more clinical results from their group, presented at conferences earlier this year 9, 10 . The conference proceedings sug gest that AMG 510 has broad activity in lung cancer, with tumour shrinkage observed in four patients, and cessation of tumour growth in several more. Of note, however, these data were reported at an early stage of the trial, and the results for people treated for colon cancer look less promising at this early stage. It will be interesting to discover the longterm out comes of the patients treated by Canon and colleagues. It will also be important to investi gate whether combination strategies might be effective if these patients develop resistance to AMG 510 treatment.
Many questions remain. Could AMG 510 be more suitable as the firstline treatment for cancers involving KRAS G12C than the current standard treatments, which involve chemo therapy or immunotherapy? Could the new inhibitor be effective when cancers have spread to the brain (a major site for second ary tumours in KRASmutated cancer), which is associated with a high chance of death? The optimal dose of AMG 510 and any toxicity asso ciated with that dose remain to be determined. In addition, it will be interesting to see how this molecule compares with other such inhibitors in the clinic, including a recently reported 11 small molecule called MRTX849.
Nonetheless, Canon and colleagues' results provide a solid proof of concept that AMG 510 treatment results in cancercell death, and highlight a putative mechanism by which the molecule acts. Moreover, the work validates the assumption that it is KRAS G12C (rather than another unidentified mutant protein) that drives the cancers that carry this mutation. It also provides support for targeting KRAS therapeutically, and represents a major step towards bringing KRAS inhibition to the clinic. Finally, the authors have revealed an intriguing link between a targeted cancer therapy and immune responses. Further study of this rela tionship might lead to the discovery of new combination therapies for cancer. 
